NCT06355401Not yet recruitingPhase 2/3
Maintenance Hormonal Therapy and DLBCL
Effect of Maintenance Hormonal Therapy on the Outcome of Patients With DLBCL
Source: ClinicalTrials.gov · Last updated 9 Apr 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
the study aims to detect the benefit of maintenance tamoxifen after achieving CR with conventional immuno-chemotherapy and/or radiotherapy in patients with DLDCL
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 4 Apr 2024
- Start date
- 1 Apr 2024
- Primary completion date
- 31 Mar 2026
- Lead sponsor
- Sohag University
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT06355401
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 100
- From 1 Apr 2024 to the primary completion date, 31 Mar 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- less than 18 years or older than 75 years other types of lymphoid neoplasms cardiac comorbidity
Who the study is looking for
- adults 18-75 years old newly diagnosed DLBCL patients who achieve CR after conventional primary treatment can be included PS 0-2
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.